Based in Wilmington, Delaware, Incyte Corporation (INCY) is a global biopharmaceutical company that discovers, develops, and commercializes innovative treatments for cancer, blood disorders, and immune-mediated diseases.
The company’s marketed therapies include JAKAFI for blood cancer, ICLUSIG for leukemia, PEMAZYRE for bile-duct cancer, MONJUVI/MINJUVI for lymphoma, and NIKTIMVO for fibrotic disease. Incyte is also advancing a growing clinical pipeline to treat additional cancers, myeloproliferative neoplasms, inflammatory diseases, and rare disorders.
More News from Barchart
These efforts have helped the company reach a market cap of approximately $25.3 billion, putting it above the $10 billion threshold commonly used to classify large-cap stocks.
The stock is currently trading…




